A new insight on evaluation of the fertility and pregnancy outcome in patients with primary Sjögren syndrome: a propensity score matched study in multi-IVF centers

• Published in: Reproductive biology and endocrinology Vol. 22; no. 1; p. 57
• Main Authors: Mao, Ruolin, Zhu, Lixia, Long, Rui, Zhou, Juepu, Wang, Xiangfei, Wang, Meng, Wang, Tiantian, Li, Youzhu, Long, Hui, Jin, Lei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 20-05-2024; BioMed Central; BMC
• Subjects: Adult; Analysis; Embryonic development; Female; Female fertility; Fertility - physiology; Fertilization in vitro; Fertilization in Vitro - methods; Humans; In vitro fertilization; Infertility, Female - epidemiology; Infertility, Female - etiology; Infertility, Female - therapy; Methods; Oocyte and embryonic development; Oocytes; Ovarian Reserve - physiology; Patient outcomes; Physiological aspects; Pregnancy; Pregnancy Outcome - epidemiology; Pregnancy outcomes; Pregnancy Rate; Primary Sjögren syndrome; Propensity Score; Retrospective Studies; Sjogren's syndrome; Sjogren's Syndrome - complications; Sjogren's Syndrome - epidemiology; China; In vitro fertilization; Pregnancy outcomes; Female fertility; Primary Sjögren syndrome; Oocyte and embryonic development
• ISSN: 1477-7827; 1477-7827
• DOI: 10.1186/s12958-024-01228-4

Primary Sjögren syndrome (pSS) is often related to adverse neonatal outcomes. But it's currently controversial whether pSS has an adverse effect on female fertility and clinical pregnancy condition. More importantly, it's unclear regarding the role of pSS in oocyte and embryonic development. There is a lack of comprehensive understanding and evaluation of fertility in pSS patients.
This study aimed to investigate oocyte and embryonic development, ovarian reserve, and clinical pregnancy outcomes in Primary Sjögren syndrome (pSS) patients during in vitro fertilization (IVF) treatment from multi-IVF centers.
We performed a muti-central retrospective cohort study overall evaluating the baseline characteristics, ovarian reserve, IVF laboratory outcomes, and clinical pregnancy outcomes between the pSS patients and control patients who were matched by Propensity Score Matching.
Following PSM matching, baseline characteristics generally coincided between the two groups. Ovarian reserve including anti-müllerian hormone (AMH) and antral follicle counting (AFC) were significantly lower in the pSS group vs comparison (0.8 vs. 2.9 ng/mL, P < 0.001; 6.0 vs. 10.0, P < 0.001, respectively). The pSS group performed significant reductions in numbers of large follicles, oocytes retrieved and MII oocytes. Additionally, pSS patients exhibited obviously deteriorate rates of oocyte maturation, 2PN cleavage, D3 good-quality embryo, and blastocyst formation compared to comparison. As for clinical pregnancy, notable decrease was found in implantation rate (37.9% vs. 54.9%, P = 0.022). The cumulative live birth rate (CLBR) following every embryo-transfer procedure was distinctly lower in the pSS group, and the conservative and optimal CLBRs following every complete cycle procedure were also significantly reduced in the pSS group. Lastly, the gestational weeks of the newborns in pSS group were distinctly early vs comparison.
Patients with pSS exhibit worse conditions in terms of female fertility and clinical pregnancy, notably accompanied with deteriorate oocyte and embryo development. Individualized fertility evaluation and early fertility guidance are essential for these special patients.